Rising Pharmaceuticals admitted to fixing prices on a medicine used to treat hypertension, the Department of Justice announced. The New Jersey-based drugmaker also entered a deferred prosecution agreement with the government....
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: